Claims for Patent: 5,994,409

Summary for Patent: 5,994,409

Title:	Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
Abstract:	The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
Inventor(s):	Stogniew; Martin (Blue Bell, PA), Alberts; David S. (Tucson, AZ), Kaplan; Edward H. (Skokie, IL)
Assignee:	U.S. Bioscience, Inc. (West Conshohocken, PA) The Arizona Board of Regents on behalf of the University of Arizona (Tuscon, AZ)
Application Number:	08/987,550
Patent Claims:	1. A method for treating toxicities associated with the administration of a chemotherapeutic agent to a human, which comprises administering a therapeutically effective amount of one or more aminothiol compounds, or a pharmaceutically acceptable salt thereof, to said human after one or more of said toxicities have occurred, wherein said aminothiol compound is WR-638, WR-2529, WR-77913, or a compound of the formula: or a pharmaceutically acceptable addition salt or hydrate thereof, wherein R.sub.1 is hydrogen, C.sub.5 -C.sub.7 aryl, C.sub.2 -C.sub.7 acyl, or C.sub.1 -C.sub.7 alkyl; R.sub.2 is hydrogen, PO.sub.3 H.sub.2 or R.sub.3 wherein R.sub.3 is R.sub.1 NH(CH.sub.2).sub.n NH(CH.sub.2).sub.m S--; n is an integer from 1 to 10; and m is an integer from 1 to 10. 2. The method of claim 1 wherein said aminothiol is selected from the group consisting of WR-1065, WR-151326, WR-151327, WR-3689, WR-2822, WR-255591, WR-2823, WR-255709 and salts and hydrates thereof. 3. The method of claim 1 wherein said aminothiol is amifostine. 4. The method of claim 1 wherein said aminothiol is WR-33278. 5. The method of claim 1 wherein said aminothiol is an active metabolite of WR-2721. 6. The method of claim 1 wherein said aminothiol is a prodrug of a active metabolite of WR-2721. 7. The method of claim 1 wherein said toxicity is selected from the group consisting of neurotoxicity, nephrotoxicity, ototoxicity, cardiotoxicity, alopecia, mucositis, xerostomia, infertility, pulmonary toxicity and renal failure. 8. The method of claim 1 wherein said aminothiol is administered one or more days after the occurrence of said toxicity. 9. The method of claim 1 wherein two or more aminothiol compounds are administered. 10. The method of claim 1 wherein said therapeutically effective amount administered is from about 10 mg/m.sup.2 to about 2,000 mg/m.sup.2. 11. The method of claim 1 wherein said human is a cancer patient, an AIDS patient, a diabetic, or hypertensive patient. 12. The method of claim 1 wherein said chemotherapeutic agent is an antineoplastic agent. 13. The method of claim 12 wherein said antineoplastic agent is cisplatin, carboplatin, paclitaxel, docetaxel, vinblastine, vincristine, navelbine, gemcytobin, etoposide, doxorubicin, daunorubicin or a combination thereof. 14. A method of treating toxicities associated with the exposure of a human to antineoplastic radiation therapy which comprises administering a therapeutically effective amount of one or more aminothiol compounds, or a pharmaceutically acceptable salt thereof, to said human after one or more of said toxicities have occurred, wherein said aminothiol compound is WR-638, WR-2529, WR-77913, or a compound of the formula: or a pharmaceutically acceptable addition salt or hydrate thereof, wherein R.sub.1 is hydrogen, C.sub.5 -C.sub.7 aryl, C.sub.2 -C.sub.7 acyl, or C.sub.1 -C.sub.7 alkyl; R.sub.2 is hydrogen, PO.sub.3 H.sub.2 or R.sub.3 wherein R.sub.3 is RINH(CH.sub.2).sub.n NH(CH.sub.2).sub.m S--; n is an integer from 1 to 10; and m is an integer from 1 to 10. 15. The method of claim 14 where in said aminothiol compound is selected from the group consisting of WR-1065, WR151326, WR151327, WR-3689, WR-2822, WR-255591, WR-2823, WR-255709 and salts or hydrates thereof. 16. The method of claim 14 wherein said aminothiol is amifostine. 17. The method of claim 14 wherein said aminothiol is WR-33278. 18. The method of claim 14 wherein said aminothiol is an active metabolite of WR-2721. 19. The method of claim 14 wherein said aminothiol is a prodrug of a active metabolite of WR-2721. 20. The method of claim 14 wherein said toxicity is selected from the group consisting of neurotoxicity, nephrotoxicity, ototoxicity, cardiotoxicity, alopecia, mucositis, xerostomia, infertility, pulmonary toxicity and renal failure. 21. The method of claim 20 wherein said aminothiol is administered one or more days after the occurrence of toxicity. 22. The method of claim 20 wherein two or more aminothiol compounds are administered. 23. The method of claim 20 wherein the amount administered is from about 10 mg/M.sup.2 to about 2,000 mg/m.sup.2. 24. The method of claim 20 wherein said human is a cancer patient. 25. The method of claim 14 wherein said radiation therapy is x-ray radiation, nuclear radiation or gamma radiation. 26. The method of claim 1 or 20 wherein said aminothiol compound is administered intravenously, subcutaneously, intramuscularly, intradermally, topically or orally. 27. A method for treating toxicities associated with the administration of a chemotherapeutic agent which comprises administering to a human after one or more of said toxicities have occurred, a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable addition salt or hydrate thereof; wherein R is hydrogen or an alkyl group having 1 to 7 carbon atoms and m and n each independently have a value from 1 to 10. 28. The method of claim 27 wherein the compound is amifostine. 29. A method for treating toxicities associated with exposure to antineoplastic radiation therapy, which comprises administering to a human after one or more of said toxicities have occurred, a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable addition salt or hydrate thereof; wherein R is hydrogen or an alkyl group having 1 to 7 carbon atoms and m and n each independently have a value from 1 to 10. 30. The method of claim 27 wherein the compound is amifostine. 31. A method for treating a nephrodisorder associated with the administration of cisplatin to a human which comprises administering to said human after said nephrodisorder has occurred, a therapeutically effective amount of amifostine, or a pharmaceutically acceptable salt or hydrate thereof. 32. A method for treating xerostomia induced in a human by antineoplastic chemotherapy or antineoplastic radiation therapy, which comprises administering to said human in need thereof a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable addition salt or hydrate thereof, wherein R.sub.1 is hydrogen, C.sub.5 -C.sub.7 aryl, C.sub.2 -C.sub.7 acyl, or C.sub.1 -C.sub.7 alkyl; R.sub.2 is hydrogen, PO.sub.3 H.sub.2 or R.sub.3 wherein R.sub.3 is R.sub.1 NH(CH.sub.2).sub.n NH(CH.sub.2).sub.m S--; n is an integer from 1 to 10; and m is an integer from 1 to 10. 33. A method for treating xerostomia induced in a human by antineoplastic chemotherapy or antineoplastic radiation therapy which comprises administering to said human in need thereof a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable addition salt or hydrate thereof; wherein R is hydrogen or an alkyl group having 1 to 7 carbon atoms, and m and n each independently have a value from 1 to 10. 34. The method of claim 32 wherein the aminothiol compound is amifostine. 35. The method of claim 33 wherein the compound is amifostine. 36. The method of claim 12, wherein said antineoplastic agent is cisplatin. 37. The method of claim 1, 14, 27 or 29 wherein the toxicity is nephrotoxicity. 38. The method of claim 1, 14, 27 or 29 wherein the administering of one or more of said aminothiol compounds is made after the first indication of one or more of said toxicities. 39. The method of claim 1, 14, 27 or 29 wherein the administering of one or more of said aminothiol compounds is made after one or more of said toxicities have appeared and have been established. 40. A method for treating a neurodisorder associated with the administration of cisplatin to a human which comprises administering to said human after said neurodisorder has occurred a therapeutically effective amount of amifostine, or a pharmaceutically acceptable salt or hydrate thereof.